Association of Prolactin, Oxytocin, and Homocysteine With the Clinical and Cognitive Features of a First Episode of Psychosis Over a 1-Year Follow-Up.
First-episode psychosis
cognition
homocysteine
oxytocin
prolactin
Journal
The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
received:
03
04
2023
accepted:
20
08
2023
medline:
27
11
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
The clinical debut of schizophrenia is frequently a first episode of psychosis (FEP). As such, there is considerable interest in identifying associations between biological markers and clinical or cognitive characteristics that help predict the progression and outcome of FEP patients. Previous studies showed that high prolactin, low oxytocin, and high homocysteine are factors associated with FEP 6 months after diagnosis, at which point plasma levels were correlated with some clinical and cognitive characteristics. We reexamined 75 patients at 12 months after diagnosis to measure the evolution of these molecules and assess their association with clinical features. At follow-up, FEP patients had lower prolactin levels than at baseline, and patients treated with risperidone or paliperidone had higher prolactin levels than patients who received other antipsychotic agents. By contrast, no changes in oxytocin and homocysteine plasma levels were observed between the baseline and follow-up. In terms of clinical features, we found that plasma prolactin and homocysteine levels were correlated with the severity of the psychotic symptoms in male FEP patients, suggesting that they might be factors associated with psychotic symptomatology but only in men. Together with oxytocin, these molecules may also be related to sustained attention, verbal ability, and working memory cognitive domains in FEP patients. This study suggests that focusing on prolactin, oxytocin, and homocysteine at a FEP may help select adequate pharmacological treatments and develop new tools to improve the outcome of these patients, where sex should also be borne in mind.
Sections du résumé
BACKGROUND
BACKGROUND
The clinical debut of schizophrenia is frequently a first episode of psychosis (FEP). As such, there is considerable interest in identifying associations between biological markers and clinical or cognitive characteristics that help predict the progression and outcome of FEP patients. Previous studies showed that high prolactin, low oxytocin, and high homocysteine are factors associated with FEP 6 months after diagnosis, at which point plasma levels were correlated with some clinical and cognitive characteristics.
METHODS
METHODS
We reexamined 75 patients at 12 months after diagnosis to measure the evolution of these molecules and assess their association with clinical features.
RESULTS
RESULTS
At follow-up, FEP patients had lower prolactin levels than at baseline, and patients treated with risperidone or paliperidone had higher prolactin levels than patients who received other antipsychotic agents. By contrast, no changes in oxytocin and homocysteine plasma levels were observed between the baseline and follow-up. In terms of clinical features, we found that plasma prolactin and homocysteine levels were correlated with the severity of the psychotic symptoms in male FEP patients, suggesting that they might be factors associated with psychotic symptomatology but only in men. Together with oxytocin, these molecules may also be related to sustained attention, verbal ability, and working memory cognitive domains in FEP patients.
CONCLUSION
CONCLUSIONS
This study suggests that focusing on prolactin, oxytocin, and homocysteine at a FEP may help select adequate pharmacological treatments and develop new tools to improve the outcome of these patients, where sex should also be borne in mind.
Identifiants
pubmed: 37603404
pii: 7246690
doi: 10.1093/ijnp/pyad051
pmc: PMC10674080
doi:
Substances chimiques
Prolactin
9002-62-4
Oxytocin
50-56-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
796-807Subventions
Organisme : Spanish Ministry of Economy and Competiveness
ID : PI1100325
Organisme : Madrid Regional Government
ID : S2017/BMD-3740
Organisme : Government of the Principality of Asturias
ID : PCTI-2021-2023 IDI/2021/111
Organisme : ERDF
Organisme : Department of Economy, Knowledge, Business
ID : FEDER-UCA18-106933
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of CINP.
Références
Int J Neuropsychopharmacol. 2014 Oct 31;18(2):
pubmed: 25577666
Schizophr Res. 2012 Aug;139(1-3):201-6
pubmed: 22742979
Dialogues Clin Neurosci. 2015 Dec;17(4):463-76
pubmed: 26869847
Schizophr Res. 2010 Dec;124(1-3):13-21
pubmed: 20947304
Schizophr Res. 2019 Apr;206:13-20
pubmed: 30573406
Psychoneuroendocrinology. 2017 Jan;75:141-151
pubmed: 27825069
Arch Gen Psychiatry. 1976 Jun;33(6):766-71
pubmed: 938196
Schizophr Res. 2016 Jul;174(1-3):156-160
pubmed: 27068570
J Psychopharmacol. 2010 Jul;24(7):1011-8
pubmed: 19825908
Psychol Med. 2013 Dec;43(12):2571-82
pubmed: 23590895
Harv Rev Psychiatry. 2013 Sep-Oct;21(5):219-47
pubmed: 24651556
PLoS One. 2014 Feb 24;9(2):e89428
pubmed: 24586772
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
Am J Psychiatry. 2010 Jun;167(6):686-93
pubmed: 20360319
CNS Drugs. 2016 Mar;30(3):193-208
pubmed: 26895254
Lancet Psychiatry. 2021 Oct;8(10):883-891
pubmed: 34474013
Psychosom Med. 2011 Jun;73(5):393-400
pubmed: 21636661
Aust N Z J Psychiatry. 2016 May;50(5):410-72
pubmed: 27106681
J Neurosci Res. 2002 Dec 1;70(5):694-702
pubmed: 12424737
Biol Psychiatry. 2008 Jul 1;64(1):4-10
pubmed: 18466880
Schizophr Bull. 2023 Jan 3;49(1):78-89
pubmed: 36334051
Psychoneuroendocrinology. 2019 Apr;102:24-36
pubmed: 30503781
Schizophr Res. 2012 Aug;139(1-3):116-28
pubmed: 22658527
Schizophr Bull. 2014 Mar;40(2):376-87
pubmed: 23486748
Neurosci Biobehav Rev. 2017 Sep;80:36-56
pubmed: 28506922
Schizophr Res. 2017 Nov;189:134-141
pubmed: 28223031
Schizophr Bull. 2019 Sep 11;45(5):1101-1111
pubmed: 30321434
Schizophr Bull. 2015 Mar;41(2):483-93
pubmed: 24962607
Biomedicines. 2022 Oct 28;10(11):
pubmed: 36359260
Aust N Z J Psychiatry. 2018 Jun;52(6):585-595
pubmed: 29232966
Psychopharmacology (Berl). 1981;73(2):184-7
pubmed: 6785813
CNS Drugs. 2014 May;28(5):421-53
pubmed: 24677189
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Psychiatr Danub. 2019 Jun;31(Suppl 2):148-152
pubmed: 31158115
Schizophr Res. 1994 Feb;11(3):273-6
pubmed: 7910756
Psychoneuroendocrinology. 2003 Jan;28 Suppl 1:53-67
pubmed: 12504072
Schizophr Res. 2008 Jan;98(1-3):247-55
pubmed: 17961988
Schizophr Res. 2013 May;146(1-3):138-43
pubmed: 23465965
Antioxidants (Basel). 2023 Jan 15;12(1):
pubmed: 36671064
Expert Opin Investig Drugs. 2000 Apr;9(4):819-28
pubmed: 11060712
Curr Psychiatry Rep. 2019 Sep 14;21(10):100
pubmed: 31522306
Neurosci Lett. 2017 May 22;650:168-173
pubmed: 28419824
Int J Psychiatry Clin Pract. 2016 Sep;20(3):165-9
pubmed: 27334805
Acta Psychiatr Scand. 2020 Oct;142(4):319-325
pubmed: 32740913
Psychopharmacology (Berl). 1996 Mar;124(1-2):159-67
pubmed: 8935812
J Neurosci. 2000 Sep 15;20(18):6920-6
pubmed: 10995836
Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
pubmed: 6639293
Arch Womens Ment Health. 2019 Jun;22(3):367-373
pubmed: 30097769
Rev Psiquiatr Salud Ment. 2013 Jan-Mar;6(1):4-16
pubmed: 23206389
J Psychiatr Res. 2019 May;112:38-43
pubmed: 30849617
Biol Psychiatry. 2004 Sep 1;56(5):301-7
pubmed: 15336511
Psychiatry Res. 2016 Jul 30;241:207-20
pubmed: 27183106
Schizophr Res. 2011 Aug;130(1-3):266-70
pubmed: 21684122
Psychoneuroendocrinology. 1985;10(2):187-91
pubmed: 4034849
Brain Struct Funct. 2020 Jan;225(1):285-304
pubmed: 31820102
Channels (Austin). 2014;8(3):193-202
pubmed: 24758841
Arch Gen Psychiatry. 2007 Jan;64(1):19-28
pubmed: 17199051
Int J Neuropsychopharmacol. 2022 Aug 16;25(8):666-677
pubmed: 35353882
Schizophr Res. 2012 Jan;134(1):16-9
pubmed: 21831600
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1921-6
pubmed: 18824063
Eur Arch Psychiatry Clin Neurosci. 2000;250(6):304-10
pubmed: 11153965
Front Psychiatry. 2021 Mar 19;12:643112
pubmed: 33815175
Mol Psychiatry. 2006 Feb;11(2):143-9
pubmed: 16172608
Psychiatry Res. 1994 Jul;53(1):31-40
pubmed: 7991730
J Psychiatr Res. 2021 Apr;136:428-434
pubmed: 32948308